vs
CLEANSPARK, INC.（CLSK）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是CLEANSPARK, INC.的1.1倍（$207.3M vs $181.2M），Ultragenyx Pharmaceutical Inc.净利率更高（-62.0% vs -209.0%，领先147.0%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 11.6%），Ultragenyx Pharmaceutical Inc.自由现金流更多（$-100.8M vs $-198.1M），过去两年CLEANSPARK, INC.的营收复合增速更高（106.4% vs 38.0%）
CleanSpark Inc.是一家总部位于美国的可持续技术企业，核心业务包含两大板块：一是依托可再生能源与闲置能源开展低碳比特币挖矿业务，二是为北美地区的工商业及公共部门客户提供微电网设计、部署与运营服务。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
CLSK vs RARE — 直观对比
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $181.2M | $207.3M |
| 净利润 | $-378.7M | $-128.6M |
| 毛利率 | 47.2% | — |
| 营业利润率 | -174.7% | -54.7% |
| 净利率 | -209.0% | -62.0% |
| 营收同比 | 11.6% | 25.9% |
| 净利润同比 | -253.5% | 3.5% |
| 每股收益（稀释后） | — | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $181.2M | $207.3M | ||
| Q3 25 | — | $159.9M | ||
| Q2 25 | — | $166.5M | ||
| Q1 25 | — | $139.3M | ||
| Q4 24 | — | $164.6M | ||
| Q3 24 | $89.3M | $139.5M | ||
| Q2 24 | $104.1M | $147.0M | ||
| Q1 24 | $111.8M | $108.8M |
| Q4 25 | $-378.7M | $-128.6M | ||
| Q3 25 | — | $-180.4M | ||
| Q2 25 | — | $-115.0M | ||
| Q1 25 | — | $-151.1M | ||
| Q4 24 | — | $-133.2M | ||
| Q3 24 | $-62.2M | $-133.5M | ||
| Q2 24 | $-236.2M | $-131.6M | ||
| Q1 24 | $126.7M | $-170.7M |
| Q4 25 | 47.2% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 36.0% | — | ||
| Q2 24 | 56.6% | — | ||
| Q1 24 | 69.3% | — |
| Q4 25 | -174.7% | -54.7% | ||
| Q3 25 | — | -106.9% | ||
| Q2 25 | — | -64.8% | ||
| Q1 25 | — | -102.6% | ||
| Q4 24 | — | -74.3% | ||
| Q3 24 | -73.5% | -94.6% | ||
| Q2 24 | -239.2% | -79.1% | ||
| Q1 24 | — | -151.9% |
| Q4 25 | -209.0% | -62.0% | ||
| Q3 25 | — | -112.8% | ||
| Q2 25 | — | -69.0% | ||
| Q1 25 | — | -108.5% | ||
| Q4 24 | — | -80.9% | ||
| Q3 24 | -69.6% | -95.7% | ||
| Q2 24 | -226.9% | -89.5% | ||
| Q1 24 | 113.4% | -156.8% |
| Q4 25 | — | $-1.28 | ||
| Q3 25 | — | $-1.81 | ||
| Q2 25 | — | $-1.17 | ||
| Q1 25 | — | $-1.57 | ||
| Q4 24 | — | $-1.34 | ||
| Q3 24 | — | $-1.40 | ||
| Q2 24 | — | $-1.52 | ||
| Q1 24 | — | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $458.1M | $421.0M |
| 总债务越低越好 | $1.8B | — |
| 股东权益账面价值 | $1.4B | $-80.0M |
| 总资产 | $3.3B | $1.5B |
| 负债/权益比越低杠杆越低 | 1.29× | — |
8季度趋势，按日历期对齐
| Q4 25 | $458.1M | $421.0M | ||
| Q3 25 | — | $202.5M | ||
| Q2 25 | — | $176.3M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | — | $174.0M | ||
| Q3 24 | $121.2M | $150.6M | ||
| Q2 24 | $126.1M | $480.7M | ||
| Q1 24 | — | $112.3M |
| Q4 25 | $1.8B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $7.2M | — | ||
| Q2 24 | $1.3M | — | ||
| Q1 24 | $5.1M | — |
| Q4 25 | $1.4B | $-80.0M | ||
| Q3 25 | — | $9.2M | ||
| Q2 25 | — | $151.3M | ||
| Q1 25 | — | $144.2M | ||
| Q4 24 | — | $255.0M | ||
| Q3 24 | $1.8B | $346.8M | ||
| Q2 24 | $1.4B | $432.4M | ||
| Q1 24 | $1.5B | $140.3M |
| Q4 25 | $3.3B | $1.5B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | $2.0B | $1.5B | ||
| Q2 24 | $1.5B | $1.6B | ||
| Q1 24 | $1.5B | $1.3B |
| Q4 25 | 1.29× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | 0.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-161.1M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $-198.1M | $-100.8M |
| 自由现金流率自由现金流/营收 | -109.3% | -48.6% |
| 资本支出强度资本支出/营收 | 20.4% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-626.9M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $-161.1M | $-99.8M | ||
| Q3 25 | — | $-91.4M | ||
| Q2 25 | — | $-108.3M | ||
| Q1 25 | — | $-166.5M | ||
| Q4 24 | — | $-79.3M | ||
| Q3 24 | $-233.7M | $-67.0M | ||
| Q2 24 | $-58.4M | $-77.0M | ||
| Q1 24 | $-44.8M | $-190.7M |
| Q4 25 | $-198.1M | $-100.8M | ||
| Q3 25 | — | $-92.7M | ||
| Q2 25 | — | $-110.7M | ||
| Q1 25 | — | $-167.8M | ||
| Q4 24 | — | $-79.5M | ||
| Q3 24 | $-299.8M | $-68.6M | ||
| Q2 24 | $-68.7M | $-79.0M | ||
| Q1 24 | $-60.3M | $-193.9M |
| Q4 25 | -109.3% | -48.6% | ||
| Q3 25 | — | -58.0% | ||
| Q2 25 | — | -66.5% | ||
| Q1 25 | — | -120.5% | ||
| Q4 24 | — | -48.3% | ||
| Q3 24 | -335.8% | -49.2% | ||
| Q2 24 | -66.0% | -53.7% | ||
| Q1 24 | -54.0% | -178.2% |
| Q4 25 | 20.4% | 0.5% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | 74.0% | 1.2% | ||
| Q2 24 | 9.9% | 1.4% | ||
| Q1 24 | 13.8% | 3.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.35× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLSK
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
